Pacific Biosciences of California, Inc.

    Jurisdiction
    United States
    ISIN
    US69404D1081 (PACB)
    Sectors
    1. Healthcare
    2. Medical - Devices

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Read full profile

    Fundamentals

    Net revenue
    €133.15M
    Gross margin
    21.4%
    EBIT
    -€562.02M
    EBIT margin
    -422.1%
    Net income
    -€448.96M
    Net margin
    -337.2%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €158.39M +19.0% -€134.68M -70.0%
    €197.39M +24.6% -€116.39M -13.6%
    €242.44M +22.8% -€100.20M -13.9%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Van Oene Mark See Remarks -27K $1.31 -$35.16K

    Investor transactions

    Name Shares Value Last change Change type
    Cathie Wood 36M $43.04M +434K Buy
    George Soros 1M $1.18M -1.4M Sell

    Earnings Calls

    Add to watchlist

    Notifications